Karatzas and Partners Law Firm


We acted as Greek legal counsel for MS Pharma, a leading pharmaceuticals and healthcare solutions company in the Middle East based in Amman, Jordan, which also operates in Turkey and Africa, in the acquisition of the Greek-based generics company Genepharm S.A. in the context of MS Pharma’s expansion into Europe and farther afield. Genepharm develops, manufactures and out-licenses high-value generic pharmaceutical products.  The transaction, which was completed on 30.04.2019, required extensive and specialised  legal due diligence in relation to pharmaceutical products and services, as well as complex corporate matters for a Greek company founded on and active since 1967, an in-depth analysis of the commercial relationships and agreements of Genepharm with other pharmaceutical companies and customers in Greece and abroad with regards to the licensing (in and out) and rights of use of generics’ dossiers, distribution of generics and intellectual property matters in the highly regulated pharmaceutical sector, while in parallel our team worked together with the international legal advisors in drafting, negotiating and concluding the share purchase agreement and other transaction documents. The transaction is one of the significant M&A transactions in Greece for Q1 2019 and in the Greek pharmaceuticals sector.

Karatzas & Partners Law Firm participated as sponsors in the 11th Panhellenic Convention of Legal Services Lawyers titled: “Are We Ready for the New Société Anonyme?”, organized by Nomiki Bibliothiki, Economia Group, the Association of Corporate Counsel Europe and the Athens Bar Association.

Over 300 legal advisors and financial consultants came together Friday 12th April, to discuss the framework on establishing and operating L. 4548/2018, which has been effective since January 1st 2019. On behalf of Karatzas & Partners, Alexandros Metallinos, Deputy Managing Partner, delivered a presentation, about the issues that could arise when a company transfers its corporate seat outside Greek boards.

We acted as Greek legal advisers to the successful completion of TAP’s 3.9 billion euro project financing, the largest project finance agreed for a European infrastructure project in 2018.
With the financial close achieved, TAP has reached a major milestone of the project’s progress. TAP has voluntarily committed to comply with environmental and social standards required by the international financial institutions. As such, all necessary assessments to substantiate this commitment have been undertaken and met by TAP.
The financing is provided by a group of 17 commercial banks, alongside the EBRD and the European Investment Bank (EIB). Part of the financing is covered by the export credit agencies - bpifrance, Euler Hermes and Sace. The project raised EUR 3765 million in third party senior debt with a door-to-door tenor of 16.5 years, combining commercial debt along with development financial institutions (DFI) and export credit agencies (ECA) related financing.

Karatzas and Partners advised Athens International Airport with the successful completion of the structuring co-arrangement and documentation signing for an up to EUR665.6m bond loan facility, by National Bank of Greece S.A. and Piraeus Bank S.A on an equal basis.

Karatzas & Partners Law Firm is proud to be a golden sponsor of this year's ELSA Athens' Summer School on International Investment Law.
ELSA Athens Summer ELSA Law School gives its participants the ticket to explore an intriguing field of law, along with their own interests. The International Investment Law is currently one of the most popular fields of international law, given the rapid increase of international investment disputes over the past few year, as well as the theoretical and practical problems arising from possible "overlaps" with other fields of international and EU law. ELSA Athens Summer ELSA Law School addresses a variety of subjects related to international investment arbitration, ranging from investors' Standards of Treatment and Host States' Defences to the implications of umbrella and denial of benefit clauses.

Page 1 of 9